scholarly journals Cost Effectiveness Analysis Using Antibiotics of Cefixime and Cefotaxime for Diarrhea Patients at X Hospital in 2017

2019 ◽  
Vol 8 (4) ◽  
pp. 145
Author(s):  
Gayatri Citraningtyas ◽  
Ranny Inggrid Ruru ◽  
Amelia Nalang
Keyword(s):  
Cost Effectiveness ◽  
Antibiotic Therapy ◽  
Cost Effective ◽  
Data Retrieval ◽  
Retrospective Data ◽  
Research Needs ◽  
Cost Effectiveness Ratio ◽  
Descriptive Research ◽  
Effectiveness Analysis ◽  
Bowel Movements

Diarrhea is a disease characterized by a change in the shape and consistency of stools, from soft to liquid, and increased frequency of bowel movements, which happen three times or more in a day. Different use of antibiotics by patients results in patient’s medical cost increase. The use of expensive antibiotics does not guarantee the effectiveness of patient care, therefore a research needs to be done to determine which antibiotic therapy is more cost effective between cefixime and cefotaxime antibiotics in hospitalized diarrhea patients in X hospital. This research was descriptive research with retrospective data retrieval. This research was conducted at Medical Record Installation and  Fund mobilization department of X hospital from November 2017 - Maret 2018. The samples in this study were 42 patients with 21 patients using Cefixime and 21 patients were using an Cefotaxime. Data was analyzed descriptively in table form. The results showed that the more cost-effective therapy between Cefixime and Cefotaxime in the treatment of diarrhea in X hospital was therapy with Cefixime antibiotic, which can be seen from ACER (Average Cost-Effectiveness Ratio) Cefixime Rp. 323.428,14/day compared with Cefotaxime ACER value of Rp. 477.180,26/day for each increase in effectiveness. The lowest ICER value on Cefixime was Rp. -50.565,8.-

scholarly journals ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ANTIBIOTIK PADA PASIEN SEPSIS DI RUMAH SAKIT SILOAM MANADO

PHARMACON ◽  
2019 ◽  
Vol 8 (4) ◽  
pp. 836
Author(s):  
Regita Langi ◽  
Widya A. Lolo ◽  
Imam Jayanto
Keyword(s):  
Cost Effectiveness ◽  
Antibiotic Therapy ◽  
Research Methods ◽  
Systemic Disease ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Descriptive Research ◽  
Effectiveness Analysis ◽  
Life Threatening

ABSTRACT Sepsis is a systemic disease that is often life-threatening in hospitals. Treatment with antibiotics is one of the important factors supporting the success of sepsis treatment. Because of the variety of antibiotic therapy given to sepsis patients, it is necessary to do a cost-effectiveness analysis to find out which treatment therapies are more cost-effective. This study aims to find out more cost-effective therapies between the treatment of cefotaxime and ceftazidim antibiotics in sepsis patients at Siloam Hospital Manado using descriptive research methods by retrospective retrieval of data from January to December 2018. The sample in this study were 19 patients consisting of 12 patients who used cefotaxime antibiotics and 7 patients who used ceftazidim antibiotics. The results showed that cefotaxime antibiotic therapy was more cost-effective with an ACER value of IDR. 873,114/day and ICER value of IDR. 176,390/day. Keyword: Cost Effectiveness Analysis, Pharmaconomics, Antibiotics, Sepsis..  ABSTRAK Sepsis merupakan penyakit sistemik yang sering mengancam jiwa di rumah sakit. Terapi dengan menggunakan antibiotik adalah faktor keberhasilan dalam pengobatan sepsis. Karena beragamnya terapi antibiotik yang diberikan kepada pasien sepsis perlu dilakukan analisis efektivitas biaya untuk dapat mengetahui terapi pengobatan mana yang lebihcost-effective. Penelitian ini bertujuan untuk mengetahui terapi yang lebih cost-effective antara pengobatan antibiotik sefotaksim dan seftazidim pada pasien sepsis di RS. Siloam Manado dengan menggunakan metode penelitian deskriptif dengan pengambilan data secara retrospektif pada periode Januari - Desember 2018. Sampel dalam penelitian ini sebanyak 19 pasien yang terdiri dari 12 pasien yang menggunakan antibiotik sefotaksim dan 7 pasien yang menggunakan antibiotik seftazidim. Hasil penelitian menunjukan terapi antibiotik sefotaksim lebih cost-effective dengan nilai ACER sebesar Rp. 873.114/hari dan nilai ICER sebesar Rp. 176.390/hari.Kata Kunci : Analisis Efektivitas Biaya, Farmakoekonomi, Antibiotik, Sepsis.

scholarly journals Cost-Effectiveness Analysis Kloramfenikol Dan Seftriakson Untuk Pengobatan Demam Tifoid Pada Pasien Dewasa Di Rumah Sakit Sanglah Denpasar

2019 ◽  
Vol 2 (2) ◽  
pp. 105-112
Author(s):  
Amelia Lorensia ◽  
Doddy De Queljoe ◽  
Made Dwike Swari Santi
Keyword(s):  
Cost Effectiveness ◽  
Length Of Stay ◽  
Typhoid Fever ◽  
Medical Records ◽  
Cost Effective ◽  
Cost Effectiveness Ratio ◽  
Hospital Perspective ◽  
Effectiveness Analysis ◽  
The Cost ◽  
Two Alternatives

The number of typhoid fever patient in Indonesia is still high. Typhoid fever can be treated by antibiotic therapy such as chloramphenicol and ceftriaxone. The purpose of this study was to compare the cost-effectiveness of chloramphenicol and ceftriaxone which was given to adult patients who were diagnosed with typhoid fever in Sanglah Denpasar Hospital. A comparative study between two alternatives was conducted using the hospital perspective. Retrospective method was used to collect data from patient medical records, who was diagnosed and hospitalized in Sanglah Denpasar Hospital during January 2017 until July 2018. The cost analysis was perform using cost-effectiveness grid and cost-effectiveness ratio (ACER) methods. Cost-effectiveness grid showed that dominant of ceftriaxone for patient with typhoid fever. ACER analysis for ceftriaxone was IDR 2,097,170.88 with effectivenes (length of stay) 4.27 days, and was IDR 2,097,170.88 with effectiveness (the time of reaching normal temperature) 2.42 days. ACER analysis for chloramphenicol was IDR 2,555,464.22        with effectivenes (length of stay) 10.22 days, and was IDR 2,555,464.22 with effectiveness (the time of reaching normal temperature) 3.44 days. ACER analysis showed lower degree of ceftriaxone and higher effectiveness based on length of stay and the time of reaching normal temperature. The conclusion of this study is that ceftriaxone is more cost-effective than chloramphenicol.

scholarly journals ANALISIS EFEKTIVITAS BIAYA PADA PASIEN ANAK DEMAM TIFOID DI RUMAH SAKIT BHAYANGKARA MANADO

PHARMACON ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 335
Author(s):  
Agatha Agnes ◽  
Gayatri Citraningtyas ◽  
Sri Sudewi
Keyword(s):  
Cost Effectiveness ◽  
Typhoid Fever ◽  
Incremental Cost ◽  
Pediatric Patients ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Incremental Cost Effectiveness Ratio ◽  
Cost Effectiveness Ratio ◽  
Effectiveness Analysis ◽  
Record Data

ABSTRACT Typhoid fever is an endemic disease which it incidence rate is still high in Indonesian. Administering antibiotic therapy can do treatment of typhoid fever. This study was conducted since there are several pediatric patients diagnosed with typhoid fever but have different antibiotic therapies, namely cefotaxime and ceftriaxone therapy, so it is necessary to do calculations to determine the comparison and determine which treatment is more efficient in cost and effectiveness. The method used in this study is CEA (Cost-Effectiveness Analysis) with the design of retrieving medical record data of children with typhoid fever in Bhayangkara Manado Hospital retrospectively from January to December 2018. The samples  obtained were 28 pediatric patients, cinsisting of 12 patients using cefotaxime therapy and 16 patients using ceftriaxone therapy. The result of ACER (An Avarage Cost Effective Ratio) obtained by ceftriaxone were Rp. 526.609,-/day and cefotaxime Rp. 484.789,-/day. In this study, if patients under cefotaxime therapy want to swich treatment to ceftriaxone therapy, ICER calculation (Incremental Cost-Effectiveness Ratio) is carried out the result are Rp.340.528,-. Keyword: Typhoid fever, Antibiotics, CEA (Cost-Effectiveness Analysis) ABSTRAK Demam tifoid merupakan penyakit endemik yang angka kejadiannya masih tinggi di Indonesia. Pengobatan demam tifoid dapat diobati dengan cara pemberian terapi antibiotik. Penelitian ini dilakukan karena ada beberapa pasien anak yang di diagnosa demam tifoid tetapi memiliki terapi antibiotik yang berbeda, yaitu terapi sefotaksim dan seftriakson  sehingga perlu dilakukan perhitungan untuk mengetahui perbandingan dan menentukan pemilihan pengobatan mana yang lebih efisien dalam biaya maupun efektivitas. Metode yang digunakan dalam penelitian ini adalah CEA (Cost-Effectiveness Analysis) dengan rancangan pengambilan data rekam medik pasien anak demam tifoid di RS. Bhayangkara Manado secara retrospektif pada periode Januari – Desember 2018. Sampel yang didapat sebanyak 28 pasien anak, yang terdiri dari 12 pasien pengguna terapi sefotaksim dan 16 pasien pengguna terapi seftriakson. Hasil ACER (An Avarage Cost Effective Ratio) yang diperoleh sefotaksim Rp.526.609,-/hari dan seftriakson Rp.484.789,-/hari. Pada penelitian ini jika pasien terapi sefotaksim ingin berpindah pengobatan ke terapi seftriakson maka dilakukan perhitungan ICER (Incremental Cost-Effectiveness Ratio) dan didapat hasil Rp.340.582,-, sehingga jika ingin berpindah pengobatan maka perlu penambahan biaya sesuai nilaI ICER.Kata Kunci : Demam Tifoid, Antibiotik, CEA (Cost-Effectiveness Analysis).

scholarly journals ANALISIS EFEKTIVITAS BIAYA (COST EFFECTIVENESS ANALYSIS) PENGOBATAN INFEKSI SALURAN KEMIH MENGGUNAKAN ANTIBIOTIK SEFTRIAKSON DAN SEFOTAKSIM DI RS PARU ARIO WIRAWAN SALATIGA

2019 ◽  
Vol 1 (1) ◽  
pp. 20-26
Author(s):  
Kusumaning Wardhani ◽  
Ening Listyanti ◽  
Niken Dyahariesti ◽  
Richa Yuswantina
Keyword(s):  
Cost Effectiveness ◽  
Incremental Cost ◽  
Average Cost ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Cost Effectiveness Ratio ◽  
Effectiveness Analysis

Infeksi Saluran Kemih (ISK) adalah keadaan dimana kuman bertumbuh dan berkembangbiak di dalam traktus urinarius dengan jumlah yang bermakna. ISK diobati dengan antibiotik yang menjadi salah satu kategori biaya yang signifikan dalam anggaran farmasi di rumah sakit. Antibiotik golongan Sefalosporin digunakan sebagai drug of choise dan dicari lebih cost-effective. Untuk menentukan terapi yang lebih cost-effective antara penggunaan Setriakson dan Sefotaksim pada pasien ISK di rawat inap di RS Paru Ario Wirawan Salatiga. Penelitian ini menggunakan metode penelitian deskriptif dengan pengambilan data secara retrospektif.Dianalisis dengan metode CEA dengan parameter Average Cost Effectiveness Ratio (ACER) dan Incremental Cost Effectiviness Ratio (ICER) dilihat dari outcome lama rawat inap. Sampel pada penelitian ini sebanyak 39 pasien diantaranya 22 pasien menggunakan Seftriakson dan 17 pasien menggunakan Sefotaksim. Hasil penelitian menunjukkan, nilai ACER kelas I Sefotaksim sebesar Rp. 454.353. Nilai ACER kelas II Sefotaksim sebesar Rp. 212.283 dan nilai ICER sebesar -Rp. 134.987/hari. Nilai ACER kelas III Seftriakson sebesar Rp. 268.366. Biaya antibiotik yang paling cost-effective pada kelas I adalah Sefotaksim, paling cost-effective pada kelas II adalah Sefotaksim, paling cost-effective pada kelas III adalah Seftriakson.

scholarly journals COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE GENERIC AND PATENT IN CHILDREN WITH TYPHOID

2018 ◽  
Vol 10 (1) ◽  
pp. 76
Author(s):  
Santi Purna Sari ◽  
Icut Diki Adestia Putri ◽  
Binar Nursanti
Keyword(s):  
Cost Effectiveness ◽  
Hospital Stay ◽  
Analytical Study ◽  
Length Of Hospital Stay ◽  
Cost Effective ◽  
Physician Service ◽  
Cost Effectiveness Ratio ◽  
Cross Sectional ◽  
Effectiveness Analysis ◽  
Laboratory Examinations

Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effectivetreatment.Methods: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total samplingmethod. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectivenessof the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costsof drugs, laboratory examinations, medical device usage, physician service, and hospitalization.Results: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day.Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.

scholarly journals COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey

Vaccines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 399
Author(s):  
Arnold Hagens ◽  
Ahmet Çağkan İnkaya ◽  
Kasirga Yildirak ◽  
Mesut Sancar ◽  
Jurjen van der Schans ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Savings ◽  
Cost Effective ◽  
Incremental Cost Effectiveness Ratio ◽  
Vaccine Uptake ◽  
First Year ◽  
Cost Effectiveness Ratio ◽  
Scenario Analyses ◽  
Effectiveness Analysis ◽  
The Cost

As of March 2021, COVID-19 has claimed the lives of more than 2.7 million people worldwide. Vaccination has started in most countries around the world. In this study, we estimated the cost-effectiveness of strategies for COVID-19 vaccination for Turkey compared to a baseline in the absence of vaccination and imposed measures by using an enhanced SIRD (Susceptible, Infectious, Recovered, Death) model and various scenarios for the first year after vaccination. The results showed that vaccination is cost-effective from a health care perspective, with an incremental cost-effectiveness ratio (ICER) of 511 USD/QALY and 1045 USD/QALY if vaccine effectiveness on transmission is equal or reduced to only 50% of effectiveness on disease, respectively, at the 90% baseline effectiveness of the vaccine. From a societal perspective, cost savings were estimated for both scenarios. Other results further showed that the minimum required vaccine uptake to be cost-effective would be at least 30%. Sensitivity and scenario analyses, as well as the iso-ICER curves, showed that the results were quite robust and that major changes in cost-effectiveness outcomes cannot be expected. We can conclude that COVID-19 vaccination in Turkey is highly cost-effective or even cost-saving.

scholarly journals ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ERITROPOETIN (HEMAPO® , EPOTREX®, NEORECORMON®) PADA PASIEN HEMODIALISIS DI RSUP PERSAHABATAN

2018 ◽  
Vol 18 (3) ◽  
Author(s):  
Chandra Widianti ◽  
Yusi Anggriani ◽  
Tri Kusumaeni ◽  
Okpri Meila
Keyword(s):  
Cost Effectiveness ◽  
Health Care Providers ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Care Providers ◽  
Cost Effectiveness Ratio ◽  
Effectiveness Analysis ◽  
Level Increase ◽  
Therapy Cost ◽  
Case Base

Abstrak. Penerapan INA-CBGs (Indonesia Case Base Groups) di era JKN mendorong penyedia layanan kesehatan, untuk menghitung biaya yang dikeluarkan agar tidak merugi. Pada pasien Gagal Ginjal Kronis (GGK) yang menjalani hemodialisis, prevalensi anemia cukup tinggi, sehingga diberikan eritropoetin (EPO). Dibutuhkan penelitian untuk mengetahui dari beberapa jenis EPO, mana yang lebih cost-effective. Penelitian deskriptif non-eksperimental dilakukan di Unit Hemodialisa Rumah Sakit Persahabatan. Efektivitas terapi ditentukan oleh peningkatan kadar hemoglobin (Hb) setelah 3 (tiga) bulan berturut-turut mendapatkan terapi EPO yang sama. Analisis efektivitas-biaya diperoleh dengan menghitung nilai CER (Cost-Effectiveness Ratio). Hasil menunjukkan penggunaan Neorecormon® memiliki efektivitas yang lebih tinggi dengan persentase jumlah pasien yang mengalami peningkatan Hb sebesar 56,41% dibandingkan Hemapo® (54%) dan Epotrex® (52,63%). Total biaya pengobatan rata-rata dengan Hemapo® , Epotrex® dan Neorecormon® masing-masing Rp. 32.552.117, Rp. 34.787.487 dan Rp. 32.866.969. Hasil perhitungan nilai CER dalam penggunaan Neorecormon® untuk pasien yang mengalami peningkatan Hb adalah Rp 58.264.437, lebih kecil daripada Hemapo® (Rp. 60.281.698) and Epotrex® (Rp. 66.098.208). Berdasarkan nilai CER dan tabel efektivitas-biaya, menunjukkan bahwa Neorecormon® adalah pilihan terapi yang lebih cost-effective daripada Hemapo® dan Epotrex®.Kata-kata kunci: Analisis efektivitas-biaya, hemodialisis, eritropoetinAbstract. INA-CBGs (Indonesia Case Base Groups) in JKN era, encourages health care providers to calculate costs incurred so as not to lose money. In Chronic Renal Failure (CRF) patients who undergo hemodialysis, anemia prevalence is high enough to require administration of erythropoietin (EPO). It’s necessary to investigate the therapeutic treatment from several types of EPO, which is more cost-effective. Descriptive non-experimental research conducted in the Hemodialysis Unit in Persahabatan Hospital. The effectiveness determined by an increased in hemoglobin (Hb) levels after three (3) months earned the same EPO therapy. Cost-effectiveness analysis is obtained by calculated the CER (Cost-Effectiveness Ratio). The results shows that Neorecormon® have a higher effectiveness with the percentage of patients whose Hb level increase by 56.41% comparing to Hemapo® (54%) and Neorecormon® (52.63%). The average total cost with Hemapo®, Epotrex® and Neorecormon® each successive Rp. 32.552.117, Rp. 34.787.487 and Rp. 32.866.969. The CER value of Neorecormon® show cost-effectiveness of Rp 58.264.437 for a patient with an increase in Hb, smaller than Hemapo® (Rp. 60.281.698) and Epotrex® (Rp. 66.098.208). Based on CER value and cost effectiveness grid, shows that Neorecormon® is the choice that is more cost-effective than Hemapo® and Epotrex®. Keywords : Cost effectiveness analysis, hemodialysis, erythropoetin

scholarly journals Optimal Control of Shigellosis with Cost-Effective Strategies

2020 ◽  
Vol 2020 ◽  
pp. 1-15
Author(s):  
Stephen Edward ◽  
Nyimvua Shaban ◽  
Eunice Mureithi
Keyword(s):  
Optimal Control ◽  
Cost Effectiveness ◽  
Optimal Control Theory ◽  
Cost Effective ◽  
Incremental Cost Effectiveness Ratio ◽  
Cost Effectiveness Ratio ◽  
Effective Strategies ◽  
Education Campaign ◽  
Effectiveness Analysis ◽  
The Cost

In this paper, we apply optimal control theory to the model for shigellosis. It is assumed that education campaign, sanitation, and treatment are the main controls for this disease. The aim is to minimize the number of infections resulting from contact with careers, infectious population, and contaminated environments while keeping the cost of associated controls minimum. We achieve this aim through the application of Pontryagin’s Maximum Principle. Numerical simulations are carried out by using both forward and backward in time fourth-order Runge-Kutta schemes. We simulate the model under different strategies to investigate which option could yield the best results. The findings show that the strategy combining all three control efforts (treatment, sanitation, and education campaign) proves to be more beneficial in containing shigellosis than the rest. On the other hand, cost-effectiveness analysis is performed via incremental cost-effectiveness ratio (ICER). The findings from the ICER show that a strategy incorporating all three controls (treatment, sanitation, and education campaign) is the most cost-effective of all strategies considered in the study.

scholarly journals Cost-effectiveness analysis of influenza A (H1N1) chemoprophylaxis in unified health system in Brazil

2019 ◽  
Author(s):  
Luisa Von Zuben Vecoso ◽  
Tais Freire Galvao ◽  
Marcus Silva ◽  
Everton Silva ◽  
Mariangela Resende
Keyword(s):  
Cost Effectiveness ◽  
Health System ◽  
Influenza A ◽  
Cost Effective ◽  
Cost Effectiveness Ratio ◽  
Tree Model ◽  
Unified Health System ◽  
Effectiveness Analysis ◽  
Influenza A H1n1 ◽  
Effectiveness Data

BACKGROUND: Oseltamivir and zanamivir have indication for treating symptomatic flu and in prophylaxis in epidemics for groups with high risk of complications. METHODS: Effectiveness data was identified in literature review, and costs were obtained from official systems and micro-costing. RESULTS: We adopted a decision-tree model to assess the effectiveness of chemoprophylaxis in Brazilian Unified Health System (SUS) perspective with willingness to pay BRL 30,000.00/QALY. The incremental cost-effectiveness ratio for chemoprophylaxis compared to no prophylaxis was - 2,921.14/QALY. CONCLUSION: Chemoprophylaxis is cost-effective in Brazilian scenario.

scholarly journals COST-EFFECTIVENESS ANALYSIS OF COUNSELING IN THERAPY FOR OUTPATIENTS WITH HYPERTENSION

2018 ◽  
Vol 11 (13) ◽  
pp. 18
Author(s):  
Diah Ramadhani ◽  
Urip Harahap ◽  
Azizah Nasution
Keyword(s):  
Cost Effectiveness ◽  
Health Care Providers ◽  
Cost Effective ◽  
Care Providers ◽  
Cost Effectiveness Ratio ◽  
Effectiveness Analysis ◽  
Quasi Experimental ◽  
Group A ◽  
The Cost ◽  
The Impact

 Objectives: To determine the effect of counseling on effectiveness and cost of the treatment for outpatient with primary hypertension (HTN) in Cut Meutia Hospital, Indonesia.Methods: This 6-month prospective quasi-experimental study was undertaken to analyze the impact of counseling toward cost and effectiveness in the treatment in patients with primary HTN and evaluation of each month at Cut Meutia Hospital, Indonesia. The study sample consisted of 22 patients for each group. A cost analysis was conducted from the perspective of the health-care providers. The cost in the treatment of both groups was analyzed by calculating the cost-effectiveness ratio (CER) and incremental CER (ICER).Results: Most of the patients with HTN (54.55%) were males with ages ranging from 35 to 64 years old (77.27%). Patients who achieved a blood pressure <140/90 mmHg on HTN treatment: With counseling, 77.27%; without counseling, 18.18%. CER for HTN treatment with and without counseling were Rp 1,756,117,86 and Rp 6,704,247,91, respectively. The ICER was Rp 233,745.13.Conclusion: Treatment of HTN with counseling was more cost-effective than without counseling.

Sign in / Sign up

Export Citation Format

Share Document